RR-1752

N/A

Report date: 2023/12/26 18:02:50

Base Information

Drug NameRR-1752
Drug Alias NameRR-1752
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho-associated kinases inhibitorsSerine/threonine-protein kinase Aurora-A inhibitorsSerine/threonine-protein kinase Aurora-B inhibitors +[4] 
TargetsRho-associated kinasesSerine/threonine-protein kinase Aurora-ASerine/threonine-protein kinase Aurora-B +[4] 
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMount Sinai School Of MedicineTranslational Drug Development
China Registration ClassN/A

Develop Information

Active CompaniesTranslational Drug DevelopmentMount Sinai School Of Medicine
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisMyeloproliferative DisordersLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A